Publications

ISCHEMIA Manuscripts

Newman JD, Anthopolos R, Ruggles KV, Cornwell M, Reynolds HR, Bangalore S, Mavromatis K, Held C, Wallentin L, Kullo IJ, McManus B, Newby LKK, Rosenberg Y, Hochman JS, Maron DJ, Berger  JS on behalf of the ISCHEMIA Biorepository Research Group. Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials. American Heart Journal. December 2023. Link

Stone GW, Ali ZA, O’Brien SM, Rhodes G, Genereux P, Bangalore S, Mavromatis K, Horst J, Dressler O, Poh KK, Nath RK, Moorthy N, Witkowski A, Dwivedi SK, Bockeria O, Chen J, Smanio PEP, Picard MH, Chaitman BR, Berman DS, Shaw LJ, Boden WE, White HD, Fremes SE, Rosenberg Y, Reynolds HR, Spertus JA, Hochman JS, Maron DJ on behalf of the ISCHEMIA Research Group. Impact of Complete Revascularization in the ISCHEMIA Trial. Journal of the American College of Cardiology. 19 September 2023:1175 – 1188. Link

Davis EF, Crousillat DR, Peteiro J, Lopez-Sendon J, Senior R, Shapiro MD, Pellikka PA, Lyubarova R, Alfakih K, Abdul-Nour K, Anthopolos R, Xu Y, Kunichoff DM, Fleg JL, Spertus JA, Hochman J, Maron D, Picard MH, Reynolds HR on behalf of the CIAO-ISCHEMIA Research Group. Global Longitudinal Strain as Predictor of Inducible Ischemia in No Obstructive Coronary Artery Disease in the CIAO-ISCHEMIA Study. Journal of the American Society of Echocardiography. 15 September 2023. Link

Mavromatis K, Jones PG, Ali ZA, Stone GW, Rhodes GM, Bangalore S, O’Brien S, Genereux P, Horst J, Dressler O, Goodman S, Alexander K, Mathew A, Chen J, Bhargava B, Uxa A, Boden WE, Mark DB, Reynolds HR, Maron DJ, Hochman JS, Spertus JA on behalf of the ISCHEMIA Research Group. Complete Revascularization and Angina-Related Health Status in the ISCHEMIA Trial. Journal of the American College of Cardiology. 25 July 2023:295 – 313. Link

Nguyen DD, Spertus JA, Alexander KP, Newman JD, Dodson JA, Jones PG, Stevens SR, O’Brien SM, Gamma R, Perna GP, Garg P, Vitola JV, Chow BJW, Vertes A, White HD, Smanio PEP, Senior R, Held C, Li J, Boden WE, Mark DB, Reynolds HR, Bangalore S, Chan PS, Stone GW, Arnold SV, Maron DJ, Hochman JS. Health status and clinical outcomes in older adults with chronic coronary disease. Journal of the American College of Cardiology. 2023;81:1697–1709.  Link, Link to Editorial

Sidhu MS, Alexander KP, Huang Z, Mathew RO, Newman JD, O'Brien SM, Pellikka PA, Lyubarova R, Bockeria O, Briguori C, Kretov EL, Mazurek T, Orso F, Roik MF, Sajeev C, Shutov EV, Rockhold FW, Borrego D, Balter S, Stone GW, Chaitman BR, Goodman SG, Fleg JL, Reynolds HR, Maron DJ, Hochman JS, Bangalore S on behalf of the ISCHEMIA-CKD Research Group. Cause-Specific Mortality in Patients with Advanced Chronic Kidney Disease in the ISCHEMIA-CKD Trial. JACC: Cardiovascular Intervantions 2023 Jan 24. Link

Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracon R, Lopez-Sendon J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ on behald of the ISCHEMIA-EXTEND Research Group. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation2022 Nov 06. Link

Mavromatis K, Boden WE, Maron DJ, Mancini GBJ, Wientraub WS, Gosselin G, Berman DS, Shaw LS, Spertus JA, Hochman JS. Comparison of Outcomes of Invasive or Conservative Management of Chronic Coronary Disease in Four Randomized Controlled Trials. The American Journal of Cardiology. 2022 Oct 15. Link

Anthopolos R, Maron DJ, Bangalore S, Reynolds HR, Xu Y, O'Brien SM, Troxel AB, Mavromichalis S, Chang M, Contreras A, Hochman JS on behalf of ISCHEMIA-EXTEND Research Group. American Heart Journal. 2022 Oct 04. Link

Mathew RO, Maron DJ, Anthopolos R, Fleg JL, O'Brien SM, Rockhold FW, Briguori C, Roik MF, Mazurek T, Demkow M, Malecki R, Ye Z, Kaul U, Miglinas M, Stone GW, Wald R, Charytan DM, Sidhu MS, Hochman JS, Bangalore. Guideline-Directed Medical Therapy Attainment and Outcomes in Dialysis-Requiring Versus Nondialysis Chronic Kidney Disease in the ISCHEMIA-CKD Trial. AHA Journals. 2022 Oct 04. Link

Reynolds HR, Diaz A, Cyr DD, Shaw LJ, Mancini GBJ, Leipsic J, Budoff MJ, Min JK, Hague CJ, Berman DS, Chaitman BR, Picard MH, Hayes SW, Scherrer-Crosbie M, Kwong RY, Lopes RD, Senior R, Dwivedi SK, Miller TD, Chow BJW, de Silva R, Stone GW, Boden WE, Bangalore S, O;Brien SM, Hochman JS, Maron DJ on behalf of the ISCHEMIA Research Group. ISCHEMIA with Nonobstructive Coronary Arteries: Insights From the ISCHEMIA Trial. JACC: Cardiovascular Imaging. 2022 Sep 14. Link

Garcia RA, Spertus JA, Benton MC, Jones PG, Mark DB, Newman JD, Bangalore S, Boden WE, Stone GW, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group. Association of Medication Adherence With Health Outcomes in the ISCHEMIA Trial. J Am Coll Cardiol. 2022 Aug 23;80(8):755-765. doi: 10.1016/j.jacc.2022.05.045. PMID: 35981820. Link

Chaitman BR, Cyr DD, Alexander KP, Pracoń R, Bainey KR, Mathew A, Acharya A, Kunichoff DF, Fleg JL, Lopes RD, Sidhu MS, Anthopolos R, Rockhold FW, Stone GW, Maron DJ, Hochman JS, Bangalore S. Cardiovascular and Renal Implications of Myocardial Infarction in the ISCHEMIA-CKD Trial. Circ Cardiovasc Interv. 2022 Aug;15(8):e012103. doi: 10.1161/CIRCINTERVENTIONS.122.012103. Epub 2022 Aug 16. PMID: 35973009. Link

Rodriguez F, Hochman JS, Xu Y, Reynolds HR, Berger JS, Mavromichalis S, Newman JD, Bangalore S, Maron DJ. Screening for participants in the ISCHEMIA trial: Implications for clinical research. J Clin Transl Sci. 2022 Jul 13;6(1):e90. doi: 10.1017/cts.2022.428. PMID: 36003207; PMCID: PMC9389278. Link

Bangalore S, Hochman JS, Stevens SR, Jones PG, Spertus JA, O'Brien SM, Reynolds HR, Boden WE, Fleg JL, Williams DO, Stone GW, Sidhu MS, Mathew RO, Chertow GM, Maron DJ. Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. JAMA Cardiol. 2022 Aug 1;7(8):825-835. doi: 10.1001/jamacardio.2022.1763. PMID: 35767253; PMCID: PMC9244774. Link

Sidhu MS, Alexander KP, Huang Z, O'Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, Maron DJ. Causes of Cardiovascular and Non-Cardiovascular Death in the ISCHEMIA Trial. American Heart Journal. June 2022. Link

Maron DJ, Bangalore S, Reynolds HR, Hochman JS. Revascularization and survival in multivessel coronary artery disease in ischemia. JTCVS Open. 2022 Apr 14;10:243. doi: 10.1016/j.xjon.2022.03.006. PMID: 36004229; PMCID: PMC9390338. Link

Bangalore S, Spertus JA, Stevens SR, Jones PG, Mancini GBJ, Leipsic J, Reynolds HR, Budoff MJ, Hague CJ, Min JK, Boden WE, O’Brien SM, Harrington RA, Berger JS, Senior R, Peteiro JPandit N, Bershtein L, de Belder MA, Szwed H, Doerr R, Monti L, Alfakih K, Hochman JS, Maron DJ on behalf of the ISCHEMIA Research Group. Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. Circulation: Cardiovascular Interventions. 2022;15:e010925. Link 

Briguori C, Mathew RO, Huang Z, Mavromatis K, Hickson LJ, Lau WL, Mathew A, Mahajan S, Wheeler DC, Claes KJ, Chen G, Nolasco FEB, Stone GW, Fleg JL, Sidhu MS, Rockhold FW, Chertow GM, Hochman JS, Maron DJ, Bangalore S. Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD. J Am Heart Assoc. 2022 Mar 15;11(6):e022003. doi: 10.1161/JAHA.121.022003. Epub 2022 Mar 9. PMID: 35261290; PMCID: PMC9075321. Link

Mark DB, Spertus JA, Bigelow R, Anderson S, Daniels MR, Anstrom KJ, Baloch KN, Cohen DJ, Held C, Goodman SG, Bangalore S, Cyr D, Reynolds HR, Alexander KP, Rosenberg Y, Stone GW, Maron DJ on behalf of the ISCHEMIA Research Group. Comprehensive Quality of Life Outcomes with Invasive versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. AHA Journals. Mar 9 2022 Link

Senior R, Reynolds HR, Min JK, Berman DS, Picard MH, Chaitman BR, Shaw LJ, Page CB, Govindan SC, Lopez-Sendon J, Peteiro J, Wander GS, Drozdz J, Marin-Neto J, Selvanayagam JB, Newman JD, Thuaire C, Christopher J, Jang JJ, Kwong RY, Bangalore S, Stone GW, O'Brien SM, Boden WE, Maron DJ, Hochman JS; ISCHEMIA Research Group. Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. J Am Coll Cardiol. 2022 Feb 22;79(7):651-661. doi: 10.1016/j.jacc.2021.11.052. PMID: 35177194; PMCID: PMC8875308. Link

Bainey KR, Fleg JL, Hochman JS, Kunichoff DF, Anthopolos R, Chernyavskiy AM, Demkow M, Lopez-Quijano JM, Escobedo J, Keong Poh K, Ramos RB, Lima EG, Schuchlenz H, Ali ZA, Stone GW, Maron DJ, O'Brien SM, Spertus JA, Bangalore S. Predictors of outcome in the ISCHEMIA-CKD trial: Anatomy versus ischemia. American Heart Journal. 2022. 243:187-200. Link

Newman JD, Anthopolos R, Mancini GBJ, Bangalore Sripal, Reynolds HR, Kunichoff DF, Senior R, Peteiro Jesus, Bhargava B, Garg P,  Escobedo J, Doerr R, Mazurek T, Gonzalez-Juanatey J, Gajos G, Briguori C, Cheng H, Vertes A, Mahajan S, Guzman LA, Matyas K, Maggioni AP, Stone GW, Berger JS, Rosenberg YD, Boden WE, Chaitman BR, Fleg JL, Hochman JS, Maron DJ. Outcomes of Participants with Diabetes in the ISCHEMIA Trials. AHA Journals. Sep 15 2021 Link

Lopez-Sendon  JL, Cy DD, Mark DB, Bangalore S, Huang Z, White HD, Alexander KP, Li J, Nair RG, Dembow M, Peteiro J, Wander GS, Demchenko EA, Gamma R, Gadkari M, Poh KK, Nageh T, Stone PH, Matyas K, Sidhu M, Newman JD, Boden WE, Reynolds HR, Chaitman BR, Hochman JS, Maron DJ, O'Brien SM forthe ISCHEMIA Research Group. Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. European Heart Journal. 2021 Sep 13. Link

Reynolds HR, Picard MH, Spertus JA, Peteiro J, Lopez-Sendon JL, Senior R, El-Hajjar MC, Celutkiene J, Shapiro MD, Pellikka PA., Kunichoff DF, Anthopolos R, Alfakih K, Abdul-Nour K, Khouri M, Bershtein L, De Belder M, Poh KK, Beltrame JF, Min JK, Fleg JL, Li Y, Maron DJ, Hochman JS. Natural History of Patients with Ischemia and No Obstructive Coronary Artery Disease: The CIAO-ISCHEMIA Study. Circulation. 2021 Jun 01. DOI: 10.1161/CIRCULATIONAHA.120.046791. Link

Lopes RD, Alexander KP, Hochman JS, Maron DJ. Response by Lopes et al to Letter Regarding Article, "Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease Patients with a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial." Circulation. 2021;143:e961–e962. Link

Herzog CA, Simegn MA, Xu Y, Costa SR, Mathew RO, El-Hajjar MC, Gulati S, Maldonado RA, Daugas E, Madero M, Fleg JL, Anthopolos R, Stone GW, Sidhu MS, Maron DJ, Hochman JS, Bangalore S. Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. Epublished DOI: 10.1016/j.jacc.2021.05.001 Link

White HD, O’Brien SM, Alexander KP, Boden WE, Bangalore S, Li J, Manjunath CN, Lopez-Sendon JL, Peteiro J, Gosselin G, Berger JS, Maggioni AP, Reynolds HR, Hochman JS, Maron DJ. Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management: A Prespecified Analysis of the ISCHEMIA Trial. JAMA Cardiology. May 03 2021 Link

Ali ZA, Horst J, Gaba P, Shaw LJ, Bangalore S, Hochman JS, Maron DJ, Moses JW, Alfonso MA, Madhavan MV, Dressler O, Reynolds HR, Stone GW. Standardizing the Definition and Analysis Methodology for Complete Coronary Artery Revascularization. J Am Heart Assoc. 2021;10:e020110. DOI: 10.1161/JAHA.120.020110 Link

Chaitman BR, Alexander KP, Cyr DD, Berger JS, Reynolds HR, Bangalore S, Boden WE, Lopes RD, Demkow M, Piero Perna G, Riezebos RK, McFalls EO, Banerjee S, Bagai A, Gosselin G, O'Brien SM, Rockhold FW, Waters DD, Thygesen KA, Stone GW, White HD, Maron DJ, Hochman JS and Group IR. Myocardial Infarction in the ISCHEMIA Trial: Impact of Different Definitions on Incidence, Prognosis, and Treatment Comparisons. Circulation. 2021;143:790-804. Link

Mancini GBJ, Leipsic J, Budoff MJ, Hague CJ, Min JK, Stevens SR, Reynolds HR, O'Brien SM, Shaw LJ, Manjunath CN, Mavromatis K, Demkow M, Lopez-Sendon JL, Chernavskiy AM, Gosselin G, Schuchlenz H, Devlin GP, Chauhan A, Bangalore S, Hochman JS, Maron DJ. Coronary CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. JACC Cardiovasc Imaging. Jan 07 2021:S1936-878X(20)31019-6. doi: 10.1016/j.jcmg.2020.11.012. Epub ahead of print. PMID: 33454249. Link

AHA Journals. Aug 29 2020 Link

Bangalore S, Maron D, Stone GW, Hochman J. Routine Revascularization versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. AHA Journals.

Spertus JA, Jones PG, Maron DJ, Mark DB, O'Brien SM, Fleg JL, Reynolds HR, Stone GW, Sidhu MS, Chaitman BR, Chertow GM, Hochman JS, Bangalore S. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. The New England Journal of Medicine. April 23 2020 Link

Bangalore S, Maron DJ, O'Brien SM, Fleg JL, Kretov EI, Briguori C, Kaul U, Reynolds HR, Mazurek T, Sidhu MS, Berger JS, Mathew RO, Bockeria O, Broderick S, Pracon S, Herzog CA, Huang Z, Stone GW, Boden WE, Newman JD, Ali ZA, Mark DB, Spertus JA, Alexander KP, Chaitman BR, Chertow GM, Hochman JS. Management of Coronary Disease in Patients with Advanced Kidney Disease. The New England Journal of Medicine. April 23 2020 Link

Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O'Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold FW, Broderick S, Ferguson Jr. TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y. Initial Invasive or Conservative Strategy for Stable Coronary Disease. The New England Journal of Medicine. April 9 2020 Link

Spertus JA, Jones PG, Maron DJ, O'Brien SM, Reynolds HR, Rosenberg Y, Stone GW, Harrell FE, Boden WE, Weintraub WS, Baloch K, Mavromatis K, Diaz A, Gosselin G, Newman JD, Mavromichalis S, Alexander KP, Cohen DJ, Bangalore S, Hochman, JS, Mark DB. Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. The New England Journal of Medicine. April 9 2020 Link

Reynolds HR, Shaw LJ, Min JK, Spertus JA, Chaitman BR, Berman DS, Picard MH, Kwong RY, Bairey-Merz CN, Cyr DD, Lopes RD, Lopez-Sendon JL, Held C, Szwed H, Senior R, Gosselin G, Nair RG, Elghamaz A, Bockeria O, Chen J, Chernyavskiy AM, Bhargava B, Newman JD, Hinic SB, Jaroch J, Hoye A, Berger J, Boden WE, O'Brien SM, Maron DJ, Hochman JS. Association of Sex With Severity of Coronary Artery Disease, Ischemia, and Symptom Burden in Patients With Moderate or Severe Ischemia Secondary Analysis of the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology. March 30, 2020 Link

Newman JD, Alexander KP, Gu X, O'Brien S, Boden WE, Govindan SC, Senior R, Moorthy N, Rezende PC, Demkow M, Lopez-Sendon JL, Bockeria O, Pandit N, Gosselin G, Stone PH, Spertus JA, Stone GW, Fleg JL, Hochman JS, Maron DJ. Baseline predictors of low-density lipoprotein cholesterol and systolic blood pressure goal attainment after 1 year in the ISCHEMIA trial. Circulation Originally published 13 Nov 2019. Link

Spertus, J. Mark, D. “ISCHEMIA Trial Update”. Am Heart J. 2019 Dec;218:8. Link

Hochman JS, Reynolds HR, Bangalore S, O'Brien S, Alexander KP, Senior R, Boden WE, Stone G, Goodman S, Lopes R, Lopez-Sendon J, White H, Maggioni A, Shaw L, Min J, Picard M, Berman D, Chaitman B, Mark D, Spertus J, Cyr D, Bhargava B, Ruzyllo W, Wander G, Chernyavskiy A, Rosenberg Y, Maron DJ. Baseline characteristics of participants in the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA). JAMA Cardiology 2019. Link

Maron DJ, Harrington RA, Hochman JS. Planning and conducting the ISCHEMIA trial: Setting the record straight. Circulation 2018;138:1384–1386. Link

Bangalore S, Maron DJ, Fleg JL, O'Brien SM, Herzog CA, Stone GW, Mark DB, Spertus JA, Alexander KP, Sidhu MS, Chertow GM, Boden WE, Hochman JS; ISCHEMIA-CKD Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. Am Heart J 2018;205:42-52. Link

Bangalore S, Maron DJ, Reynolds HR, Stone GW, O'Brien SM, PhD; ALexander KP, Hochman JS. ISCHEMIA: Establishing the primary end point. Circ Cardiovasc Qual Outcomes. 2018 May;11 (5):e004791. doi:10.1161/CIRCOUTCOMES. 118.004791. Noabstract available. PMID: 29752391. Link

Hochman JS, Maron DJ. Letter by Hochman and Maron regarding article, "'Faith Healing' and 'Subtraction Anxiety' in unblinded trials of procedures: Lessons from DEFER and FAME-2 for end points in the ISCHEMIA trial." Circ Cardiovasc Qual Outcomes 2018 Apr;11(4):e004742. doi: 10.1161/CIRCOUTCOMES.118.004742. Link

ISCHEMIA Trial Research Group, MaronDJ, Hochman JS, O'Brien SM, Reynolds HR, Boden WE, Stone GW, Bangaore S, Spertus JA, Mark DB, Alexander KP, Shaw L, Berger JS, Ferguson TB Jr, William DO, Harrington RA, Rosenberg Y. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. Am Heart J. 2018 Apr 21;201:124-135. doi: 10.1016/j.ahj.2018.04.011. PMID:29778671. Link

Bagai A, Alexander KP, Berger JS, Senior R, Sajeev C, Pracon R, Mavromatis K, Lopez-Sendón JL, Gosselin G, Diaz A, Perna G, Drozdz J, Humen D, Petrauskiene B, Cheema AN, Phaneuf D, Banerjee S, Miller TD, Kedev S, Schuchlenz H, Stone GW, Goodman SG, Mahaffey KW, Jaffe AS, Rosenberg YD, Bangalore S, Newby LK, Maron DJ, Hochman JS, Chaitman BR. The use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. Am Heart J. 2017 Aug;190:135-139. doi: 10.1016/j.ahj.2017.04.016. Epub 2017 Jun 16. PMID:28760208. Link

Kataoka A, Scherrer-Crosbie M, Dajani KA, Garceau P, Hastings JL, Kohn JA, Srbinovska-Kostovska E, Poggio D, Saric M, Senior R, Sokhon K, Shaw L, Reynolds H, Picard MH. Transient ischemic dilatation during stress echocardiography: an additional marker of significant myocardial ischemia. Echocardiography. 2016 Apr 3. doi: 10.1111/echo.13222. Link

Kataoka A, Scherrer-Crosbie M., Senior R, Gosselin G, Phaneuf D, Guzman G, Perna G, Lara A, Kedev S, Mortara A, El-Hajjar M, Shaw LJ, Reynolds HR, Picard MH. The value of core lab stress echocardiography interpretations: observations from the ISCHEMIA trial. Cardiovasc Ultrasound. 2015;13:47. Link

 

About Us

ISCHEMIA, ISCHEMIA-CKD, and ISCHEMIA-EXTEND represent the contribution of over 300 sites in 38 countries. Click here to see contributing sites by country.

Who We Are Now

  • ISCHEMIA-EXTEND is sponsored by a grant from the U.S. National Heart, Lung, and Blood Institute of the National Institutes of Health.
  • The ISCHEMIA-EXTEND is led by Judith Hochman (Trial Chair), David Maron (Principal Investigator/Trial Co-Chair).
  • New York University (NYU) Grossman School of Medicine is the Clinical Coordinating Center. NYU Grossman School of Medicine and Duke Clinical Research Institute (DCRI) collaborate as the Statistical and Data Coordinating Centers.
  • Statistical analysis of the long-term follow-up data will be led by Andrea Troxel, PhD, Director of Biostatistics at NYU, in collaboration with Sean O’Brien, PhD, PI of the Statistical and Data Coordinating Center for the ISCHEMIA Trials.

Who We Were (ISCHEMIA Trial)

  • ISCHEMIA and ISCHEMIA CKD were sponsored by a grant from the U.S. National Heart, Lung, and Blood Institute of the National Institutes of Health.
  • The ISCHEMIA Leadership Committee was Judith Hochman (Trial Chair), David Maron (Principal Investigator/Trial Co-Chair), and co-PIs William Boden, Bruce Ferguson, Robert Harrington, Gregg Stone, and David Williams.
  • The ISCHEMIA CKD PI was Sripal Bangalore.
  • New York University (NYU) was the Coordinating Center. The Statistical and Data Coordinating Center was at the Duke Clinical Research Institute (DCRI). The Imaging Coordinating Center was at Emory University and later moved to Weill Cornell Medicine. The Economics and Quality of Life Coordinating Center was at the DCRI and Mid America Heart Institute. In addition, there were the following core laboratories: angiography, nuclear imaging, echocardiograhy, cardiac MR, coronary CT angiography, and ECG.

For Patients

ISCHEMIA & ISCHEMIA-CKD Results

ISCHEMIA The ISCHEMIA trial showed that heart procedures added to taking medicines and making lifestyle changes did not reduce the overall rate of heart attack or death compared with medicines and lifestyle changes alone. However, for people with chest pain symptoms, heart procedures improved symptoms better than medicines and lifestyle changes alone. The more chest pain to begin with, the more symptoms improved after getting a stent or bypass surgery.

ISCHEMIA-CKD The ISCHEMIA-CKD trial showed that heart procedures added to taking medicines and making lifestyle changes did not result in a reduced rate of heart attack or death compared with medicines and lifestyle changes alone. The trial also showed that heart procedures did not reduce symptoms appreciably or improve the quality of life compared with medicines and lifestyle changes alone. These results do not apply to people having a heart attack or those with severe chest pain symptoms.

What is Ischemia of the Heart?

  • When a heart artery narrows, part of the heart may not receive enough blood to work normally. Doctors call this “ischemia.” The most common symptom of ischemia is chest pain (angina), but not everyone with ischemia has symptoms. Ischemia is associated with a higher risk of having a heart attack.

How is Ischemia Treated?

  • Doctors use two standard ways to treat ischemia of the heart muscle:
  1. One way (“medical therapy”) uses medicines and lifestyle changes to control symptoms and risk factors (such as smoking, high blood pressure, and high cholesterol).
  2. Another way uses an invasive procedure called cardiac catheterization to see your heart arteries, and either stents are put in the narrowed arteries to restore blood flow or surgery is done to bypass the narrowed arteries and increase blood flow to the heart muscle.  Medicines and lifestyle changes are also recommended to control risk factors.

What is a Clinical Trial?

  • A clinical trial is a research study with volunteers that is designed to discover which treatment improves results for patients. Clinical trials usually compare different treatments like medications, procedures, or devices.

What is the ISCHEMIA Trial?

  • The ISCHEMIA trial was a clinical trial that compared two standard treatments for patients with ischemia of the heart to learn which one is better and safer:
    • Starting treatment with medicines and lifestyle changes alone, with a plan to use cardiac procedures only if they are needed, OR
    • Starting treatment with invasive cardiac procedures (cardiac catheterization), and then stent placement or bypass surgery along with medicines and lifestyle changes
  • The initial phase of the ISCHEMIA Trial has been completed and we are now in the EXTENDed Follow-Up (EXTEND) phase. For ISCHEMIA Trial results, please click here

What is the ISCHEMIA-CKD Trial?

  • An international comparative effectiveness trial to determine the best way to manage chronic coronary disease in patients with advanced chronic kidney disease (eGFR <30 or on dialysis).
  • Patients with advanced CKD with moderate to severe ischemia on stress testing were randomized to this Trial. 
  • For ISCHEMIA-CKD Trial results, please click here

What is ISCHEMIA-EXTEND?

  • ISCHEMIA-EXTEND is the long-term follow-up of randomized, surviving participants in the ISCHEMIA and ISCHEMIA-CKD trials.
  • ISCHEMIA-EXTEND assesses whether an initial invasive strategy—cardiac catheterization and revascularization when feasible plus optimal medical therapy (OMT)—reduces long-term all-cause mortality as compared with an initial conservative strategy of OMT for chronic coronary disease patients with moderate or severe ischemia.

Privacy Notice:

The ISCHEMIA Coordinating Center and its identified local representatives plan to collect and use your personal and health information once, and only in the specific ways, you have granted us permission to do in the informed consent (e.g., by giving us your formal, written consent).

New York University Langone Health and Northwick Park Hospital at the London North West University Healthcare NHS Trust will serve jointly as the data controllers for purposes of this research. We will collect personal data both directly from you, and also from searches of publicly accessible databases where you have already provided consent (e.g., medical record searches in select hospitals, requests to NHS Digital). All personal data is being collected as part of a research trial that aims to provide a public benefit. Anonymized, safeguarded data will be shared with the National Institutes of Health in the United States, as is a required element of this research. Because all data is completely anonymized, we do not expect your participation to impact your individual privacy in any way.

Research subjects are entitled to withdraw consent at any time. However, in accordance with Human Research Authority, anonymized data already collected may still be used for trial-related purposes.

If you have any questions regarding your personal data, or if/how your data is used, please contact ischemia@nyulangone.org.

 
 

 

Pages